Emory Clinical Research Center in IPF

埃默里 IPF 临床研究中心

• 批准号: 6916723
• 负责人: JESSE ROMAN
• 金额: $ 19.13万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6916723
• 关键词: HMG coA reductases; atorvastatin; clinical research; clinical trial phase II; clinical trials; cooperative study; drug screening /evaluation; enzyme inhibitors; enzyme therapy; health care personnel education; health care referral /consultation; human subject; human therapy evaluation; idiopathic pulmonary fibrosis; losartan; pathologic process; patient care management; patient oriented research; renin angiotensin system; respiratory disorder chemotherapy; statistics /biometry

DESCRIPTION (provided by applicant): Idiopathic Pulmonary Fibrosis (IPF) is an idiopathic interstitial pneumonia characterized by the rapid replacement of the lung parenchyma with fibrosis which results in progressive deterioration of lung function. This process often leads to respiratory failure and death. Although several drugs are under investigation, currently there are no effective means of treating this devastating disease. This proposal is submitted in response to the NIH-sponsored RFA titled "IPF Clinical Research Network" with the intention of becoming one of the clinical research centers within this network. Our site will be based at the Emory Center for the Treatment and Study of Interstitial Lung Disease (The Emory ILD Center). The Emory ILD Center is considered a premier center for the diagnosis, treatment, and research of patients with IPF and related disorders because: 1) it currently serves as a referral base for patients with interstitial lung disease identified at any of five Emory hospitals, at several academic institutions in metro Atlanta, and through a network of private practice physicians located throughout the state of Georgia and the Southeastern region of the country; 2) it has served as a site for clinical-based investigations related to IPF and other interstitial lung diseases, and as such has developed extensive experience in clinical trials and translational research related to IPF; 3) it is staffed by a multidisciplinary team of clinical investigators, translational researchers, research coordinators, and other staff with expertise in the diagnosis and management of patients with IPF; and 4) it is directed by a team of investigators recognized in the field for their work in elucidating the mechanisms of lung tissue remodeling and fibroproliferation. The proposal describes two clinical trials to be considered by the Network that target pro-fibrotic pathways and the lung fibroblast/myofibroblast, the key effector cell responsible for fibroproliferation and tissue remodeling in pulmonary fibrosis. It also includes a Clinical Research Skills Core that will mentor junior investigators into developing the necessary skills to become independent clinician scientists involved in research related to IPF. The team of investigators leading the clinical research center and the Clinical Research Skills Core are currently engaged in clinical research related to IPF and have developed a reputation for mentoring young investigators into careers in academia. (End of Abstract)

描述（由申请人提供）： 特发性肺纤维化（IPF）是一种特发性间质性肺炎，其特征是肺实质迅速被纤维化替代，导致肺功能进行性恶化。 这个过程常常导致呼吸衰竭和死亡。 尽管有几种药物正在研究中，但目前还没有有效的方法来治疗这种毁灭性的疾病。 该提案是为了响应 NIH 赞助的名为“IPF 临床研究网络”的 RFA，旨在成为该网络内的临床研究中心之一。 我们的站点将设在埃默里间质性肺疾病治疗和研究中心（埃默里 ILD 中心）。 埃默里 ILD 中心被认为是 IPF 及相关疾病患者的诊断、治疗和研究的首要中心，因为：1) 目前，该中心是埃默里五家医院、亚特兰大都会区的几家学术机构以及通过遍布佐治亚州和该国东南部地区的私人执业医生网络确定的间质性肺病患者的转诊基地； 2) 作为IPF和其他间质性肺疾病相关临床研究的场所，在IPF相关临床试验和转化研究方面积累了丰富的经验； 3) 由临床研究者、转化研究人员、研究协调员和其他具有 IPF 患者诊断和治疗专业知识的人员组成的多学科团队组成； 4）它是由该领域公认的一组研究人员指导的，他们在阐明肺组织重塑和纤维增殖的机制方面做出了工作。 该提案描述了网络考虑的两项临床试验，分别针对促纤维化途径和肺成纤维细胞/肌成纤维细胞，肺纤维化中负责纤维增殖和组织重塑的关键效应细胞。 它还包括临床研究技能核心，将指导初级研究人员发展必要的技能，成为参与 IPF 相关研究的独立临床科学家。 领导临床研究中心和临床研究技能核心的研究人员团队目前从事与 IPF 相关的临床研究，并在指导年轻研究人员进入学术界职业方面享有盛誉。 （摘要完）